學門類別
哈佛
- General Management
- Marketing
- Entrepreneurship
- International Business
- Accounting
- Finance
- Operations Management
- Strategy
- Human Resource Management
- Social Enterprise
- Business Ethics
- Organizational Behavior
- Information Technology
- Negotiation
- Business & Government Relations
- Service Management
- Sales
- Economics
- Teaching & the Case Method
最新個案
- A practical guide to SEC ï¬nancial reporting and disclosures for successful regulatory crowdfunding
- Quality shareholders versus transient investors: The alarming case of product recalls
- The Health Equity Accelerator at Boston Medical Center
- Monosha Biotech: Growth Challenges of a Social Enterprise Brand
- Assessing the Value of Unifying and De-duplicating Customer Data, Spreadsheet Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise, Data Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise
- Board Director Dilemmas: The Tradeoffs of Board Selection
- Barbie: Reviving a Cultural Icon at Mattel (Abridged)
- Happiness Capital: A Hundred-Year-Old Family Business's Quest to Create Happiness
AstraZeneca (China): Promoting Social Innovation with Holistic Disease Management Solutions Throughout the Patient Journey
內容大綱
He increased the sales of products such as Pulmicort RespulesTM after their patents expired, generating significant social benefits by making medical treatment and medicines more accessible in lower-tier markets. Wang was promoted to President less than two years after joining AZ. While working primarily to boost sales in China, Wang introduced another task not tied to performance targets: innovation. To facilitate innovation, AZ reached beyond the pharmaceutical sector and worked with partners in the "3D" (diagnostics, device, digital) industries to launch "a patient-centric, integrated disease diagnosis and treatment platform." This initiative enabled pharmaceutical companies, which had acted only as drug suppliers during treatment, to engage in all stages of the patient journey, from education and screening, diagnosis and treatment, to follow-up and rehabilitation. Their first innovation project was the construction of pediatric nebulization centers, which were equipped with smart nebulizers powered by IoT and digital technologies. Following the initial success, AZ co-launched the chest pain center (CPC) project and the prostate cancer integrated diagnosis and treatment (PiDT) project, which not only delivered benefits to patients and hospitals but also granted partners access to hospital resources. The integrated diagnosis and treatment platform focused on areas where AZ excelled, such as respiratory and cardiovascular diseases and diabetes, so participating hospitals and patients could "naturally" choose AZ's products. However, a closer look at its sales revenue revealed that AZ was not always the primary beneficiary of the platform, and its return on investment proved to be modest.